Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) was down 3.9% on Friday . The company traded as low as C$7.09 and last traded at C$7.09. Approximately 194,163 shares traded hands during mid-day trading, an increase of 2,520% from the average daily volume of 7,410 shares. The stock had previously closed at C$7.38.
Eupraxia Pharmaceuticals Stock Down 7.8%
The stock has a fifty day moving average of C$7.14 and a two-hundred day moving average of C$7.39.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
- 3 ETFs For the Coming Genomics Revolution
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
